Cyclosporin versus tacrolimus for liver transplanted patients

E M Haddad; V C McAlister; E Renouf; R Malthaner; M S Kjaer; L L Gluud

doi:10.1002/14651858.CD005161.pub2

Cyclosporin versus tacrolimus for liver transplanted patients

E M Haddad, V C McAlister, E Renouf, R Malthaner, M S Kjaer, L L Gluud

Copenhagen Trial Unit Rigshospitalet

242 Citationer (Scopus)

Abstract

Most liver transplant recipients receive either cyclosporin or tacrolimus to prevent rejection. Both drugs inhibit calcineurin phosphatase which is thought to be the mechanism of their anti-rejection effect and principle toxicities. The drugs have different pharmacokinetic profiles and potencies. Several randomised clinical trials have compared cyclosporin and tacrolimus in liver transplant recipients, but it remains unclear which is superior.

Originalsprog	Engelsk
Tidsskrift	Cochrane Database of Systematic Reviews
Udgave nummer	4
Sider (fra-til)	CD005161
ISSN	1469-493X
DOI	https://doi.org/10.1002/14651858.CD005161.pub2
Status	Udgivet - 2006

Adgang til dokumentet

10.1002/14651858.CD005161.pub2

Citationsformater

@article{220a4b22fffd4923bdb9ac8a25afab7d,

title = "Cyclosporin versus tacrolimus for liver transplanted patients",

abstract = "Most liver transplant recipients receive either cyclosporin or tacrolimus to prevent rejection. Both drugs inhibit calcineurin phosphatase which is thought to be the mechanism of their anti-rejection effect and principle toxicities. The drugs have different pharmacokinetic profiles and potencies. Several randomised clinical trials have compared cyclosporin and tacrolimus in liver transplant recipients, but it remains unclear which is superior.",

keywords = "Cyclosporine, Graft Rejection, Graft Survival, Humans, Immunosuppressive Agents, Liver Transplantation, Randomized Controlled Trials as Topic, Tacrolimus, Time Factors",

author = "Haddad, {E M} and McAlister, {V C} and E Renouf and R Malthaner and Kjaer, {M S} and Gluud, {L L}",

year = "2006",

doi = "10.1002/14651858.CD005161.pub2",

language = "English",

pages = "CD005161",

journal = "Cochrane Database of Systematic Reviews",

issn = "1469-493X",

publisher = "Update Software Ltd",

number = "4",

}

TY - JOUR

T1 - Cyclosporin versus tacrolimus for liver transplanted patients

AU - Haddad, E M

AU - McAlister, V C

AU - Renouf, E

AU - Malthaner, R

AU - Kjaer, M S

AU - Gluud, L L

PY - 2006

Y1 - 2006

N2 - Most liver transplant recipients receive either cyclosporin or tacrolimus to prevent rejection. Both drugs inhibit calcineurin phosphatase which is thought to be the mechanism of their anti-rejection effect and principle toxicities. The drugs have different pharmacokinetic profiles and potencies. Several randomised clinical trials have compared cyclosporin and tacrolimus in liver transplant recipients, but it remains unclear which is superior.

AB - Most liver transplant recipients receive either cyclosporin or tacrolimus to prevent rejection. Both drugs inhibit calcineurin phosphatase which is thought to be the mechanism of their anti-rejection effect and principle toxicities. The drugs have different pharmacokinetic profiles and potencies. Several randomised clinical trials have compared cyclosporin and tacrolimus in liver transplant recipients, but it remains unclear which is superior.

KW - Cyclosporine

KW - Graft Rejection

KW - Graft Survival

KW - Humans

KW - Immunosuppressive Agents

KW - Liver Transplantation

KW - Randomized Controlled Trials as Topic

KW - Tacrolimus

KW - Time Factors

U2 - 10.1002/14651858.CD005161.pub2

DO - 10.1002/14651858.CD005161.pub2

M3 - Journal article

C2 - 17054241

SN - 1469-493X

SP - CD005161

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

IS - 4

ER -

Cyclosporin versus tacrolimus for liver transplanted patients

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater